Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7NKWQ)

• Drug Name: PBCAR20A Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[1]
Non-hodgkin lymphoma	2B33.5	Phase 1/2	[1]
Small lymphocytic lymphoma	2A82.0	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DM7NKWQ

Molecule-Related Drug Atlas

Drug(s) Targeting Leukocyte surface antigen Leu-16 (CD20)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[4]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[5]
Ibritumomab	DMG594T	Non-hodgkin lymphoma	2B33.5	Approved	[6]
Rituximab	DM1YVZT	Central nervous system non-hodgkin lymphoma		Approved	[7]
Ublituximab	DMHTY9W	Multiple sclerosis	8A40	Approved	[8]
Tositumomab	DMMYZ3D	Non-hodgkin lymphoma	2B33.5	Approved	[6]
Obinutuzumab	DM3BVAE	Chronic lymphocytic leukaemia	2A82.0	Approved	[9]
Ofatumumab	DM295PR	Chronic lymphocytic leukaemia	2A82.0	Approved	[10]
Rituximab	DM1YVZT	Central nervous system non-hodgkin lymphoma		Approved	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT04030195) Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Precision Biosciences.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [5] Clinical pipeline report, company report or official report of Genmab.
• [6] Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
• [7] [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
• [8] The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
• [10] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [11] Clinical pipeline report, company report or official report of Genentech (2009).